Hearst acquires CareInSync

Hearst Corporation’s healthcare group, Hearst Health, has acquired CareInSync, a software solutions company providing a real-time, mobile platform to improve patient care by enhancing communications between providers and patients. Financial terms were not disclosed.

Santa Clara, Calif.-based CareInSync, will become part of Zynx Health, which provides evidence- and experience-based clinical improvement solutions. Zynx Health, part of the Hearst Health network, began its successful relationship with CareInSync in 2012 in the form of an equity investment from Hearst’s healthcare venture fund as part of a syndicated equity funding initiative involving Hearst and other investors.

CareInSync’s technology enables its customers to connect interdisciplinary care teams that include hospital clinicians, aftercare providers and community-based service providers. CareInSync was founded in 2010 by Siva Subramanian, PhD, as a Mobile Care Navigation Network that goes beyond traditional inpatient communication and texting solutions. The CareInSync Carebook solution provides a HIPAA-compliant communication platform for the entire care team as well as context-specific messages around a person’s health milestones and evidence-based guidelines for the management and coordination of care transitions.

Effective immediately, CareInSync solutions are now available through Zynx Health.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.